Xvivo Perfusion AB (publ) XVIPF Stock
Xvivo Perfusion AB (publ) Price Chart
Xvivo Perfusion AB (publ) XVIPF Financial and Trading Overview
| Xvivo Perfusion AB (publ) stock price | 29 USD |
| Previous Close | 29 USD |
| Open | 19.33 USD |
| Bid | 25.54 USD x 10000 |
| Ask | 27.06 USD x 10000 |
| Day's Range | 19.15 - 19.33 USD |
| 52 Week Range | 16.98 - 32.9 USD |
| Volume | 200 USD |
| Avg. Volume | 8 USD |
| Market Cap | 603.21M USD |
| Beta (5Y Monthly) | 1.436 |
| PE Ratio (TTM) | 76.6 |
| EPS (TTM) | 0.24 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
XVIPF Valuation Measures
| Enterprise Value | N/A |
| Trailing P/E | 76.6 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.2881042 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Xvivo Perfusion AB (publ) Stock Price History
| Beta (5Y Monthly) | 1.436 |
| 52-Week Change | -11.85% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 32.9 USD |
| 52 Week Low | 16.98 USD |
| 50-Day Moving Average | 26.05 USD |
| 200-Day Moving Average | 21.54 USD |
XVIPF Share Statistics
| Avg. Volume (3 month) | 8 USD |
| Avg. Daily Volume (10-Days) | 11 USD |
| Shares Outstanding | 31.5M |
| Float | 25.13M |
| Short Ratio | N/A |
| % Held by Insiders | 7.84% |
| % Held by Institutions | 60.47% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 8.85% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 73.11% |
| EBITDA Margin | 16.44% |
Management Effectiveness
| Return on Assets (ttm) | 2.61% |
| Return on Equity (ttm) | 3.46% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | 10.19% |
| Gross Profit (ttm) | N/A |
| EBITDA | 137.23M USD |
| Net Income Avi to Common (ttm) | N/A |
| Diluted EPS (ttm) | 0.25 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | N/A |
| Total Cash Per Share (mrq) | N/A |
| Total Debt (mrq) | N/A |
| Total Debt/Equity (mrq) | 5.66 USD |
| Current Ratio (mrq) | 4.519 |
| Book Value Per Share (mrq) | 66.469 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | -86488496 USD |
Profile of Xvivo Perfusion AB (publ)
| Country | United States |
| State | N/A |
| City | Mölndal |
| Address | Gemenskapens gata 9 |
| ZIP | 431 53 |
| Phone | 46 3 17 88 21 50 |
| Website | https://www.xvivogroup.com |
| Industry | Medical Devices |
| Sector(s) | Healthcare |
| Full Time Employees | 199 |
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.
Q&A For Xvivo Perfusion AB (publ) Stock
What is a current XVIPF stock price?
Xvivo Perfusion AB (publ) XVIPF stock price today per share is 29 USD.
How to purchase Xvivo Perfusion AB (publ) stock?
You can buy XVIPF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Xvivo Perfusion AB (publ)?
The stock symbol or ticker of Xvivo Perfusion AB (publ) is XVIPF.
Which industry does the Xvivo Perfusion AB (publ) company belong to?
The Xvivo Perfusion AB (publ) industry is Medical Devices.
How many shares does Xvivo Perfusion AB (publ) have in circulation?
The max supply of Xvivo Perfusion AB (publ) shares is 31.5M.
What is Xvivo Perfusion AB (publ) Price to Earnings Ratio (PE Ratio)?
Xvivo Perfusion AB (publ) PE Ratio is 120.83792000 now.
What was Xvivo Perfusion AB (publ) earnings per share over the trailing 12 months (TTM)?
Xvivo Perfusion AB (publ) EPS is 0.24 USD over the trailing 12 months.
Which sector does the Xvivo Perfusion AB (publ) company belong to?
The Xvivo Perfusion AB (publ) sector is Healthcare.


